ALFA Filings
Every announcement, straight from the exchange
Every Gujarat Themis Biosyn acquisition announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
GTBL completed 100% acquisition of MBJ Japan for JPY 21.5 billion (~₹1,333 Cr). The deal adds three GMP plants and precision fermentation capabilities.
Gujarat Themis Biosyn is acquiring MicroBiopharm Japan for ₹1,300 Crore to expand its CDMO capabilities. This strategic move strengthens its position in precision fermentation and biotechnology.
Gujarat Themis Biosyn Limited will acquire 100% of Japan-based MicroBiopharm Japan for ₹1,290 Crore. This strategic acquisition expands GTBL's CDMO capabilities into advanced precision fermentation.